Aadi Bioscience Inc reports results for the quarter ended in March - Earnings Summary

Whitehawk Therapeutics

08/05/2024 15:12

* Aadi Bioscience Inc  AADI.OQ  reported a quarterly
adjusted loss
of 68 cents​​ per share for the quarter ended in March, lower
than the same quarter last year, when the company reported EPS
of -57 cents.  The mean expectation of four analysts for the
quarter was for a loss of 64 cents per share. Wall Street
expected results to range from -71 cents to -62 cents per share.
    * Revenue fell 8.8% to $5.35 million from a year ago;
analysts
expected $6.45 million. 
    * Aadi Bioscience Inc's reported EPS for the quarter was a
loss
of 68 cents​.
    * The company reported a quarterly loss of $18.29 million.
    * Aadi Bioscience Inc shares had fallen by 9.8% this
quarter and
gained 4.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $14.00 

This summary was machine generated from LSEG data May 8 at 02:12
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.64          -0.68          Missed
 Dec. 31 2023      -0.65          -0.60          Beat
 Sep. 30 2023      -0.72          -0.60          Beat
 Jun. 30 2023      -0.62          -0.67          Missed